Myra Vision

About Myra Vision

Myra Vision, a privately held portfolio company of the medical technology innovation hub Shifamed LLC, was founded in 2019 to address unmet needs in glaucoma management. The company is led by President and CEO Robert Chang, a serial entrepreneur with over 30 years of experience in the medical device industry, primarily in cardiology, before venturing into ophthalmology with Myra Vision. His background in pressure and flow dynamics from cardiology provides a relevant perspective to glaucoma treatment. Based in Campbell, California, Myra Vision operates within the surgical devices market, specifically targeting the treatment of moderate to severe glaucoma, a condition affecting a significant portion of the estimated 80 million people with glaucoma worldwide.

The company is developing the Calibreye™ Titratable Glaucoma Therapy (TGT) Surgical System, a next-generation aqueous shunt designed to provide personalized and adjustable control over intraocular pressure (IOP). Unlike traditional treatments that may lack adjustability, the Calibreye system is engineered to allow ophthalmologists to non-invasively modify aqueous outflow post-implantation. This is done during in-office visits using a standard green laser at a slit lamp, enabling physicians to tailor the treatment to a patient's evolving needs over time and potentially reduce complication rates. The implant itself is a soft, conformable aqueous shunt made of silicone and nitinol, materials with a history of safe use in the eye.

Myra Vision's business model is focused on the development and eventual commercialization of this medical device, targeting ophthalmologists and glaucoma specialists as its primary clients. The company's product is currently for investigational use and not yet for sale. A significant milestone was achieved on August 12, 2025, when the company received conditional FDA approval for an Investigational Device Exemption (IDE) to begin the ADAPT study in the United States. This prospective, non-randomized trial will assess the safety and effectiveness of the Calibreye system in up to 70 patients with refractory glaucoma. The company has successfully raised $42 million over two funding rounds, including a $25 million Series B in June 2023, to fund product development, scale manufacturing, and support clinical trials.